- Sharpest rise in CFO optimism since 2020; - Survey shows biggest decline on record for CFOs’ perceptions of external uncertainty; - Brexit and energy risks ease; - CFOs see artificial intelligence driving investment and productivity, but are divided on impact on jobs within the workforce. Sentiment among finance leaders of the UK’s largest firms has improved significantly since the start of the year, according to Deloitte’s UK CFO Survey Q1 2023. A net 25%1 of CFOs are more optimistic about the financial prospects of their business than they were three months ago. Having run well below the…

20th March 2023 Nijmegen, The Netherlands and Biocity Nottingham UK Alveron Pharma announces that it has commenced a Phase 1 clinical study for OKL-1111, a new drug for the treatment of Intracranial Haemorrhage (ICH) and other life-threatening bleeds associated with the use of anticoagulants or platelet inhibitors.  The clinical trial is taking place in the UK and will investigate safety, pharmacokinetics and pharmacodynamics in man.   ICH is a devastating condition with a 30-50% mortality rate and is also responsible for approximately 50% of disability associated with stroke…

Do you have a winning commercialisation strategy? If you are a startup that: - Is developing therapeutic innovations - Has obtained a first proof-of-concept OR a £1-3m funding - Has integrated digital technologies (ML/AI) in the R&D workflow OR is planning to Apply to SBC Catalyser programme! You'll end the free 8-week programme with: - A refined commercialisation strategy to go from prototype to commercially-viable product - A better understanding of how to improve / embed digital technologies (ML/AI) to accelerate your R&D - Access to SBC extensive network of experts, mentors…

CHARM Therapeutics is a 3D deep learning research company discovering and developing transformational medicines. The facility will act as the new research & development (R&D) site for CHARM Therapeutics, providing the Company with the necessary capacity to support its growth plans as it continues to develop its transformational oncology pipeline.  Babraham Research Campus is an internationally recognized life sciences cluster, with over 60 companies and 2,000 employees co-located with the Babraham Institute providing shared facilities and supporting programs. The Campus is one of…

The Skeletal Muscle Differentiation kit from AMSBIO provides a unique protocol to differentiate human pluripotent stem cells to skeletal muscle with high yields and without cell sorting or genetic manipulation. Now available with the option of simple to use control myoblasts, stem cell researchers looking to differentiate stem cells to skeletal muscle with multinucleated myotubes can produce consistent, high-quality results every time. Methods for studying muscular disease and potential therapies were, until recently, dependent on invasive muscle biopsies to produce limited batches of…

 April’s eNews is here to continue the #lifesciences conversation on:✅ Upcoming Events✅ Storytelling in Corporate Communication✅ Our Collaboration with United Airlines✅ Meet our Ecosystem in our Annual Review✅ ON Helix✅ Cambridge Facilities and Lab SpaceRead it here

Arecor Therapeutics plc (“Arecor” or the “Group”) ARECOR APPOINTS DR. MANJIT RAHELU AS CHIEF BUSINESS OFFICER - Manjit is an accomplished strategic deal-maker bringing 25+ years of scientific, commercial and financial experience across major global pharmaceutical and biotechnology companies, specialising in product in and out-licensing, commercial strategy, accelerating growth and M&A - Will play a key role in building and executing Arecor’s ambitious commercialisation and growth plans as pipeline of proprietary and partnered products advances Cambridge, UK, 5 April 2023: Arecor…

Arecor Therapeutics plc (“Arecor” or the “Group”) FIRST PATIENT DOSED IN SECOND PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED, ULTRA-RAPID ACTING INSULIN CANDIDATE - Disrupter insulin with potential to be the first ultra-concentrated and ultra-rapid acting insulin available for patients - AT278 aims to significantly improve post prandial glucose control and reduce injection volume and potentially enable fewer injections per day for people with Type 2 diabetes who have high insulin needs - Ultra-concentrated, ultra-rapid acting insulin such as AT278 is critical to development of next…

Contract Research Organizations (CROs) have become vital partners in the drug development process, enabling biotech and pharmaceutical companies to develop and market life-saving drugs. To further understand the supply chain complexities for CROs, Biocair recently conducted a qualitative research study with CRO supply chain professionals. The study involved 45-minute business interviews with supply chain professionals working for CROs. The results of the study have proved instrumental for Biocair in furthering its understanding of the intricacies facing CROs and how logistics play a vital…

Economic data shows uplifting effect on employment across both Knowledge Intensive (KI) and non-KI sectors in the Cambridgeshire and Peterborough region. Cambridge, UK. 4th April 2023: The latest in-depth analysis on the Cambridge city region economy from Cambridge Ahead, produced by the Centre for Business Research (CBR) at the University of Cambridge, shines a spotlight on science and innovation-led job creation that is fuelling a buoyant and resilient corporate economy, and is increasingly having a positive effect on job creation across wider (non-KI) sectors in the wider Cambridgeshire…